Risk of heart disease in relation to radiotherapy and chemotherapy with anthracyclines among 19,464 breast cancer patients in Denmark, 1977-2005

Rehammar, Jens Christian; Jensen, Maj-Britt; McGale, Paul; Laugaard Lorenzen, Ebbe; Taylor, Carolyn; Darby, Sarah C; Videbæk, Lars; Wang, Zhe; Ewertz, Marianne

Published in:
Radiotherapy & Oncology

DOI:
10.1016/j.radonc.2017.03.012

Publication date:
2017

Document version
Publisher's PDF, also known as Version of record

Document license
CC BY

Citation for published version (APA):
Rehammar, J. C., Jensen, M-B., McGale, P., Laugaard Lorenzen, E., Taylor, C., Darby, S. C., ..., Ewertz, M. (2017). Risk of heart disease in relation to radiotherapy and chemotherapy with anthracyclines among 19,464 breast cancer patients in Denmark, 1977-2005. Radiotherapy & Oncology, 123(2), 299–305. DOI: 10.1016/j.radonc.2017.03.012

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Download date: 03. Nov. 2018
Heart disease after breast cancer

Risk of heart disease in relation to radiotherapy and chemotherapy with anthracyclines among 19,464 breast cancer patients in Denmark, 1977–2005

Jens Christian Rehammar a,b, Maj-Britt Jensen c, Paul McGale d, Ebbe Laugaard Lorenzen a,b, Carolyn Taylor d, Sarah C. Darby d, Lars Videbæk e, Zhe Wang d,f,1, Marianne Ewertz a,b,1

aDepartment of Oncology, Odense University Hospital; bInstitute of Clinical Research, University of Southern Denmark; cDanish Breast Cancer Cooperative Group Secretariat, Copenhagen University Hospital, Rigshospitalet, Denmark; dNuffield Department of Population Health, University of Oxford, United Kingdom; eDepartment of Cardiology, Odense University Hospital, Denmark; fMedical Research Council Population Health Research Unit, University of Oxford, United Kingdom

Background and purpose: The risk of heart disease subsequent to breast cancer radiotherapy was examined with particular focus on women receiving anthracycline-containing chemotherapy.

Material and methods: Women diagnosed with early-stage breast cancer in Denmark, 1977–2005, were identified from the register of the Danish Breast Cancer Cooperative Group, as was information on cancer-directed treatment. Information on heart disease was sought from the Danish National Patient and Cause of Death Registries. Incidence rate ratios were estimated comparing left-sided with right-sided cancer (IRR, LvR), stratified by calendar year, age, and time since breast cancer radiotherapy.

Results: Among 19,464 women receiving radiotherapy, the IRR, LvR, was 1.11 (95% CI 1.03–1.20, \( p = 0.03 \)) for all heart disease and among those also receiving anthracyclines the IRR, LvR, was 1.32 (95% CI 1.02–1.70, \( p = 0.03 \)). This risk was highest if the treatment was given before the age of 50 years (IRR, LvR, 1.44, (95% CI 1.04–2.01)) but there was no significant trend with age or time since treatment.

Conclusions: Radiotherapy for left-sided breast cancer is associated with a higher risk of heart disease than for right-sided with the largest increases seen in women who also received anthracycline-containing chemotherapy.

© 2017 The Author(s). Published by Elsevier Ireland Ltd. Radiotherapy and Oncology 123 (2017) 299–305

This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
anthracyclines were also given, by comparing the incidence of heart disease in women with left-sided and right-sided breast cancer who received both radiotherapy and anthracyclines.

Few women diagnosed with breast cancer prior to 2000 received anthracyclines, so the previous cohort study provided little information regarding the effect of anthracyclines in addition to radiotherapy. We have therefore extended this Danish cohort to include breast cancer patients diagnosed up to the end of 2005 and followed for cardiac events until the end of 2013. In addition, we have obtained information on which women were actually given radiotherapy, rather than radiotherapy just being indicated, and also on which women were actually given chemotherapy and on the type of chemotherapy they received. The main aim of this study is to assess the risk of heart disease following breast cancer radiotherapy, especially among women who also received anthracycline-containing chemotherapy.

Methods

Material

Since 1977, the Danish Breast Cancer Cooperative Group (DBCG) has maintained a register of all women diagnosed with early-stage breast cancer in Denmark [9]. All Danish hospitals involved in the diagnosis and treatment of breast cancer patients report to the DBCG and its register is more than 95% complete. Women diagnosed with early-stage breast cancer from June 1977 to December 2005 were identified from the DBCG register. Women were excluded if they had bilateral cancer or cancer of unknown laterality, had a previous diagnosis of invasive cancer (apart from non-melanoma skin cancer), did not undergo surgery (e.g. had biopsy only), were diagnosed with breast cancer after emigration from Denmark or were aged less than 20 years or more than 80 years at diagnosis. Information on tumour characteristics and details of therapies actually received was also obtained from the DBCG register. Using the unique personal identification numbers issued to all Danish citizens, the DBCG register was linked with the Danish Register of Causes of Death (RCD) [10] for deaths since 1977, and the Danish National Patient Register (NPR) [11] for in-patient diagnoses since 1977 and outpatient diagnoses since 1995. Information was complete up to 31 December 2013. Information on prior cardiac disease, defined as ICD10-codes I00-I52 (or the corresponding ICD8-codes) at least 30 days before breast cancer diagnosis, was identified from the NPR.

The study was approved by the Danish Data Protection Agency and by the Danish Health and Medicines Authority.

Statistical analysis

Descriptive analyses were conducted by tabulating the total number of women, and the number who received radiotherapy, according to breast cancer laterality and each of a number of other characteristics. For every value of each characteristic, a Mantel–Haenszel $X^2$-test of whether the percentage given radiotherapy was the same for women with left-sided and right-sided cancer was conducted [12]. For further analyses, each woman’s contribution to the person-years at risk was calculated from six months after the date of breast cancer diagnosis and until the earliest of: diagnosis of any heart disease, 90th birthday, death, emigration, or 31 December 2013. For each endpoint of interest (all heart disease, ischemic heart disease, etc.) the total number of observed events and the person-years at risk were tabulated by calendar year of radiotherapy (starting from 1977–1980, then in 5-year groups), age at radiotherapy (starting from 20–24, then in 5-year groups) and time since radiotherapy (in 5-year groups). Tabulations were made for all women combined and for women in various different treatment categories. For women given radiotherapy, separate tabulations were made according to age at radiotherapy and years since radiotherapy. Incidence rate ratios comparing women in different categories, stratified by year, age, and time since breast cancer radiotherapy (all in 5-year groups), were estimated by logistic regression. To account for the differing numbers of women with left-sided and right-sided breast cancer, a variable taking the value of the ratio, left versus right, of the number of years at risk was included in the model, with the coefficient constrained to one. Tests of whether an individual rate ratio differed from one, of the homogeneity of the rate ratio across several different groups of women (for example those receiving different adjuvant medical treatments), and also tests for a trend in the rate ratio across several groups of women were based on the logarithms of the estimated rate ratios and their estimated variances. Calculations were performed using Stata version 13 [13].

Results

Between 1977 and 2005, 71,423 women were registered with a diagnosis of breast cancer by the DBCG. A total of 11,267 patients were excluded, leaving 60,156 women (Fig. 1). These women accrued 817,212 person-years, with a median follow up of 10.5 years (interquartile range 4.5–16.3 years).

When all 60,156 women were considered, the incidence rate ratio comparing women with left-sided breast cancer to women with right-sided breast cancer (IRR, LrV) for all heart disease was 1.05 (95% confidence interval (CI) 1.01–1.09, $p = 0.01$, Table 1). When the women were subdivided according to radiotherapy status, the IRR, LrV for the 19,464 for who received radiotherapy, was higher, at 1.11 (95% CI 1.03–1.20) and the significance level was more extreme ($p = 0.005$). In contrast, among women whose status was recorded in the DBCG as radiotherapy not indicated, radiotherapy indicated but not recorded, or radiotherapy unknown, the IRRs, LrV were closer to unity and none were significantly increased.

Among the 19,464 women (32.4%) who received radiotherapy (Table 2) slightly fewer had left-sided than right-sided breast cancer (32.0% vs 32.7%) and, with such large numbers, this 0.7% difference was statistically significant ($p = 0.05$). When the analysis was repeated separately for women with different characteristics, differences of at least 1% in the proportion given radiotherapy for left-sided versus right-sided disease were seen for women who were: aged <50 years (1.0%), aged 70–79 years (1.1%), node positive (1.2%), given anthracyclines (1.9%), and for women given other types of chemotherapy (2.3%). However, as the numbers of women in the individual categories of these characteristics were smaller, the differences were, in most cases, not statistically significant.

Among 4770 women who had prior heart disease recorded in the NPR, the percentage of women given radiotherapy was identical for women with left-sided and right-sided breast cancer. Among 3564 women receiving both radiotherapy and anthracyclines, chemotherapy dose was available for 94%, all receiving epirubicin. The median number of cycles was 7 (range 1–10), with a mean cumulative dose of 721 mg, corresponding to 410 mg/m$^2$ of epirubicin. Anthracycline dose was unavailable for the remaining 6%, who received either epirubicin or doxorubicin.

When the 19,464 women who received radiotherapy were subdivided according to patient and tumour characteristics, there was no significant heterogeneity in the IRR, LrV according to year of breast cancer radiotherapy, age at breast cancer radiotherapy, nodal status, surgery, prior heart disease or adjuvant medical treatment given ($p = 0.33$) (Table 3). There were, however, some notable differences. For women given breast radiotherapy during 2001–2005 (i.e., the period in which anthracyclines were given) the IRR, LrV was significantly increased (IRR, LrV: 1.15, 95% CI
1.01–1.31), despite the fact that there was no increase in the previous decade (IRR, LvR: 1.01, 95% CI 0.90–1.14). The IRR, LvR was significantly increased for women receiving anthracyclines (IRR, LvR: 1.32, 95% CI 1.02–1.70, \( p = 0.03 \)) and for women who did not receive systemic therapy (IRR, LvR: 1.15, 95% CI 1.02–1.31, \( p = 0.02 \)). For women given chemotherapy other than anthracyclines the IRR, LvR, was 1.13 but this did not reach statistical significance. For women given endocrine therapy only, the IRR, LvR was 1.03 (95% CI 0.91–1.17).

When all 19,464 women who received radiotherapy were considered, there were significant increases in the IRR, LvR, for ischaemic heart disease (1.18, 95% CI 1.03–1.35), angina (1.22, 95% CI 1.00–1.49) and valvular heart disease (1.39, 95% CI 1.00–1.96) (Table S1, panel a). These findings remained unchanged when the 18,130 women who did not have heart disease recorded in the Danish NPR prior to their cancer diagnosis were considered. The IRR, LvR, was 1.13 but this did not reach statistical significance. For women given endocrine therapy only, the IRR, LvR was 1.03 (95% CI 0.91–1.17).

When all 19,464 women who received radiotherapy were considered, there were significant increases in the IRR, LvR, for ischaemic heart disease (1.18, 95% CI 1.03–1.35), angina (1.22, 95% CI 1.00–1.49) and valvular heart disease (1.39, 95% CI 1.00–1.96). For women given chemotheraphy other than anthracyclines the IRR, LvR, was 1.13 but this did not reach statistical significance. For women given endocrine therapy only, the IRR, LvR was 1.03 (95% CI 0.91–1.17).

When all 19,464 women who received radiotherapy were considered, there were significant increases in the IRR, LvR, for ischaemic heart disease (1.18, 95% CI 1.03–1.35), angina (1.22, 95% CI 1.00–1.49) and valvular heart disease (1.39, 95% CI 1.00–1.96). For women given chemotheraphy other than anthracyclines the IRR, LvR, was 1.13 but this did not reach statistical significance. For women given endocrine therapy only, the IRR, LvR was 1.03 (95% CI 0.91–1.17).

When women given both radiotherapy and anthracyclines, many types of heart disease contributed to the increased IRR, LvR (Table 4). For myocardial infarction, angina, and other and ill-defined heart disease the IRR, LvR was more than doubled but only for angina was the increase statistically significant when considered alone. For heart failure, the IRR, Lvs R was 1.51 (95% CI 0.64–3.56).

When women given both radiotherapy and anthracyclines were subdivided according to the age at which radiotherapy was given, the highest IRR, LvR was for women aged less than 50 years when treated (IRR, LvR: 1.44, 95% CI 1.04–2.01, Fig. 2, panel a). However, there was no significant trend in the IRR, LvR across the three age-groups <50, 50–59, and 60+ years either for women who received anthracyclines, or for all other women given radiotherapy (Fig. 2, panel b), or for all women given radiotherapy (Fig. 2, panel c). The trend in the IRR, LvR, across time-periods 0–4, 5–9, and 10+ years after radiotherapy, was not significant for women given anthracyclines and radiotherapy, for other women given radiotherapy, or for all women given radiotherapy.

We examined the mortality rate ratios, left-sided vs right-sided, by cause of death (Table S2). Only 12 women (3 left-sided and 9 right-sided) died of heart disease among those receiving both radiotherapy and anthracyclines. The majority were registered as...
Table 2
Characteristics of 19,464 Danish women given radiotherapy for early-stage breast cancer and of the total number of women diagnosed with the disease, by laterality of cancer.

| Characteristic                                         | Women given radiotherapy/total number of women (%) | p-value: % | p-value for heterogeneity |
|--------------------------------------------------------|-----------------------------------------------------|------------|--------------------------|
|                                                        | Left-sided                                          | Right-sided|                           |
|                                                        | 1977–1989                                           | 1882/10,835 (17.4) | 1834/10,009 (18.3) | 0.07 |
|                                                        | 1990–2000                                           | 3540/13,220 (26.8) | 3279/12,397 (26.4) | 0.55 |
|                                                        | 2001–2005                                           | 4493/6936 (64.8)  | 4436/6759 (65.6)   | 0.29 |
| Age at breast cancer radiotherapy                       | <50                                                 | 3352/8076 (41.5)  | 3344/7867 (42.5)   | 0.20 |
|                                                        | 50–59                                               | 3185/8492 (37.5)  | 3088/8098 (38.1)   | 0.41 |
|                                                        | 60–69                                               | 2666/8263 (32.3)  | 2409/7631 (31.6)   | 0.35 |
|                                                        | 70–79                                               | 712/6160 (11.6)   | 708/5569 (12.7)    | 0.06 |
| Nodal status                                           | Negative                                            | 3701/15,879 (23.3) | 3469/14,823 (23.4) | 0.84 |
|                                                        | Positive                                            | 3185/8492 (37.5)  | 3088/8098 (38.1)   | 0.41 |
|                                                        | Unknown                                             | 67/1402 (4.8)     | 48/1220 (3.9)      | 0.29 |
| Surgery                                                | Mastectomy                                          | 4794/24,499 (19.6) | 4581/22,854 (20.0) | 0.19 |
|                                                        | Breast conserving surgery                           | 5121/6492 (78.9)  | 4968/6311 (78.7)   | 0.82 |
| Adjuvant medical treatment                             | Anthracyclines                                      | 1777/2517 (70.6)  | 1787/2666 (72.5)   | 0.14 |
|                                                        | Other chemotherapy                                  | 1746/3832 (45.6)  | 1735/3620 (47.9)   | 0.04 |
|                                                        | Endocrine therapy (no chemotherapy)†               | 3191/6425 (49.7)  | 3034/6116 (49.6)   | 0.95 |
|                                                        | No adjuvant medical treatment recorded‡            | 3201/18,217 (17.6) | 2993/16,963 (17.6) | 0.86 |
| Prior heart disease ‡                                   | No                                                  | 9230/28,543 (32.3) | 8900/26,843 (33.2) | 0.04 |
|                                                        | Yes                                                 | 685/2448 (28.0)   | 640/2322 (28.0)    | 0.98 |
|                                                        | Total                                               | 9915/30,991 (32.0) | 9549/29,165 (32.7) | 0.05 |

† Included tamoxifen for 5 years to premenopausal women from 1999. For postmenopausal women, tamoxifen was given for 1 year from 1977 to 1995, and for 5 years from 1996. Aromatase inhibitors were introduced in a trial setting to postmenopausal women in 1998.

‡ Women recorded as having no adjuvant medical treatment (left: 2687/11,190, right: 2504/10,475); women who were allocated to a protocolled programme for systemic therapy but with no records on systemic therapy (left: 275/6352, right: 226/5824).

++ Women recorded in the Danish National Patient Register as having heart disease prior to diagnosis of breast cancer.

Table 3
Incidence rate ratios, left-sided versus right-sided breast cancer for all heart disease by various characteristics in 19,464 Danish women given radiotherapy.

| Characteristic                                         | Number of events/number of women | Incidence ratio, left vs right (95% CI) | p-value† | p-value for heterogeneity |
|--------------------------------------------------------|----------------------------------|----------------------------------------|----------|--------------------------|
|                                                        | Left                             | Right                                  |          |                          |
|                                                        | 1977–1989                         | 402/1882                               | 329/1834 | 1.24 (1.07–1.43) | 0.004 | 0.09 |
|                                                        | 1990–2000                         | 561/3540                               | 519/3279 | 1.01 (0.90–1.14) | 0.86 |          |
|                                                        | 2001–2005                         | 519/4493                               | 443/4436 | 1.15 (1.01–1.31) | 0.03 |          |
| Age at breast cancer radiotherapy (years)              | <50                               | 311/3352                               | 302/3344 | 1.04 (0.89–1.23) | 0.57 | 0.53 |
|                                                        | 50–59                             | 432/3185                               | 382/3088 | 1.14 (0.99–1.31) | 0.07 |          |
|                                                        | 60–69                             | 556/2666                               | 434/2409 | 1.17 (1.03–1.32) | 0.02 |          |
|                                                        | 70–79                             | 183/712                                | 173/708  | 1.00 (0.81–1.23) | 1.00 |          |
| Nodal status                                           | Negative                          | 623/3701                               | 517/3469 | 1.14 (1.01–1.28) | 0.03 | 0.73† |
|                                                        | Positive                          | 849/6147                               | 769/6032 | 1.11 (1.00–1.22) | 0.04 |          |
|                                                        | Unknown                           | 10/67                                  | 5/48     | 1.66 (0.41–6.68) | 0.48 |          |
| Surgery                                                | Mastectomy                        | 701/4794                               | 610/4581 | 1.13 (1.01–1.26) | 0.03 | 0.73 |
|                                                        | Breast-conserving surgery         | 781/5121                               | 681/4968 | 1.10 (0.99–1.22) | 0.07 |          |
| Adjuvant medical treatment                             | Anthracycline                     | 140/1777                               | 109/1787 | 1.32 (1.02–1.70) | 0.03 | 0.33 |
|                                                        | Other chemotherapy                | 238/1746                               | 215/1735 | 1.13 (0.94–1.37) | 0.20 |          |
|                                                        | Endocrine therapy (no chemotherapy) | 548/3191                          | 491/3034 | 1.03 (0.91–1.17) | 0.59 |          |
|                                                        | None reported                     | 556/3201                               | 476/2993 | 1.15 (1.02–1.31) | 0.02 |          |
| Prior heart disease †                                   | No                                | 1255/9230                              | 1084/8900| 1.13 (1.04–1.22) | 0.005| 0.52 |
|                                                        | Yes                               | 227/685                               | 207/649  | 1.04 (0.86–1.28) | 0.63 |          |
|                                                        | All women given radiotherapy      | 1482/9915                              | 1291/9549| 1.11 (1.03–1.20) | 0.005|          |

† CI: Confidence Interval. Stratified by calendar year, age, and time since breast cancer radiotherapy.

‡ Test of whether incidence rate ratio is equal to unity.

Excluding unknown category.

Analysis based on the first diagnosis of heart disease occurring six months or more after the breast cancer diagnosis.
Incidence rate ratios, left-sided vs right-sided, in 3564 Danish women diagnosed with breast cancer during 1990–2005 who were given both radiotherapy and anthracyclines, by type of heart disease.

| Disease category (ICD-10 code) | Number of events Left/right | Incidence rate ratio, left vs. right\(^{\dagger}\) (95% CI) | p-value\(^{\dagger}\) |
|-------------------------------|----------------------------|----------------------------------------------------------|-----------------|
| Ischaemic heart disease (I20-25) | 32/19 | 1.71 (0.97–3.02) | 0.07 |
| Myocardial infarction (I21-23, I252) | 7/3 | 2.29 (0.59–8.90) | 0.23 |
| Angina (I20) | 21/9 | 2.36 (1.08–5.17) | 0.03 |
| Other ischaemic heart disease | 4/7 | 0.58 (0.17–2.01) | 0.39 |
| Other heart disease (I00-52 excluding I20-25) | 108/90 | 1.23 (0.93–1.64) | 0.15 |
| Hypertensive heart disease (I10-15) | 14/21 | 0.59 (0.30–1.18) | 0.14 |
| Pulmonary embolism (I26-28) | 11/8 | 1.33 (0.52–3.39) | 0.55 |
| Pericarditis (I01.0, I09.2, I30-32) | 14/8 | 1.67 (0.69–4.03) | 0.28 |
| Valvular heart disease (I00-09, I01.0, I09.2, I34-39\(^{\dagger}\)) | 8/5 | 1.96 (0.59–6.52) | 0.27 |
| Other rheumatic heart disease (I00.9) | 0/1 | - | - |
| Acute endocarditis (I33) | 1/1 | 0.99 (0.06–15.9) | 1.00 |
| Myocardial disease (I40-43) | 11/9 | 1.26 (0.52–3.03) | 0.61 |
| Conduction disorders & arrhythmias (I44-45, I47-49) | 32/26 | 1.32 (0.78–2.22) | 0.30 |
| Cardiac arrest (I46) | 1/1 | 1.06 (0.07–16.9) | 0.97 |
| Heart failure (I50) | 13/9 | 1.51 (0.64–3.56) | 0.34 |
| Other & ill-defined heart disease (I51, I52) | 3/1 | 2.68 (0.30–27.6) | 0.36 |
| All heart disease (I00-52) | 140/109 | 1.32 (1.02–1.70) | 0.03 |

1777 women had left-sided breast cancer and 1787 women had right-sided breast cancer. Analysis based on first diagnosis of heart disease six months or more after breast cancer diagnosis.

Results for other categories of women are given in Table S1.

Discussion

This study confirms previous observations that women who received radiotherapy for left-sided breast cancer had an increased risk of subsequent heart disease compared with women who received right-sided radiotherapy. The present study has examined the radiation-related increase in heart disease according to the type of systemic therapy given. It found that the proportional increase among women irradiated for left-sided cancer compared with right-sided cancer was highest for women who also received chemotherapy with anthracyclines. Among women given both anthracyclines and radiotherapy, the risk of heart disease was higher in left-sided breast cancer compared with right-sided, even though most of them had been treated since the year 2000 using modern radiotherapy techniques. This suggests that chemotherapy with anthracyclines may increase the effect of radiotherapy on the heart.

Initial exploratory analyses compared women who received adjuvant therapy with those who did not and showed that women who received adjuvant therapy had lower heart disease rates than those who did not. This suggests that women who were at higher risk of heart disease were less likely to receive radiotherapy and adjuvant medical treatment, making comparisons of women who did and did not receive such therapies biased. We have demonstrated previously [4] that radiotherapy was associated with reduced mortality from heart disease in women given breast-conserving surgery and increased mortality among other women, leading to selection bias if comparisons are made between irradiated and unirradiated women. Such comparisons should not be used to draw reliable conclusions as to the presence of any radiation-related risk.

More than thirty studies, including around a quarter of a million women irradiated for breast cancer during the past five decades, have reported heart disease rates in women irradiated for left-sided cancer compared with women irradiated for right-sided cancer [14]. In most of these studies, the left versus right cardiac event rate ratio was greater than one and, in studies where specific types of heart disease were examined, ischaemic heart disease was the type most commonly affected. Consistent with these, in the present study, among all women receiving radiotherapy during 1977–2005, the increase in heart disease among women irradiated for left-sided breast cancer compared with right-sided cancer there was a clear increase in ischaemic heart disease.

Present study has examined the radiation-related increase in heart disease according to the type most commonly affected. Consistent with these, in the present study, among all women receiving radiotherapy during 1977–2005, the increase in heart disease among women irradiated for left-sided breast cancer compared with right-sided cancer there was a clear increase in ischaemic heart disease.

Anthracyclines were introduced into adjuvant chemotherapy as part of a randomized trial for breast cancer patients in Denmark in 1990. It improves both breast cancer and overall survival [5,6]. However, several studies have shown that it can cause heart failure, with the risk increasing according to cumulative anthracycline dose [7,8]. Most studies of radiation-related heart disease have not included women who also received anthracyclines. The relationship between heart radiation dose and subsequent ischaemic heart disease has been studied in a population-based case-control study in which individual cardiac doses were estimated. The major coronary event rate increased approximately linearly with mean heart radiation dose by 7.4% per Gray (95% CI, 2.9 to 14.5; p < 0.001) [15]. This study included very few women who also received anthracyclines. Information is therefore needed on whether the slope of this dose response relationship is affected by exposure to anthracyclines and on whether breast cancer radiotherapy given in combination with anthracyclines increase the risk of heart failure.

Strengths and limitations of the study

A strength of our study is that it is based on the entire population of Danish breast cancer patients treated between 1977 and 2005. We included only women for whom there was a record that radiotherapy had actually been given, rather than just being indicated, as in previous studies from the DBCG. This will have removed the downward bias in the IRR, LvR previously caused by including women who were not, in fact, given radiotherapy. We also were able to classify women according to the type of chemotherapy given, enabling analyses of the cardiotoxic effects of radiotherapy and anthracyclines combined. Even with these stringent criteria, our study included nearly 20,000 women who received radiotherapy, 3500 of whom also received anthracyclines.
Fig. 2. Incidence rate ratios, left-sided versus right-sided breast cancer, of all heart disease in 19,464 women given radiotherapy by age at radiotherapy, years since radiotherapy, and whether or not anthracycline chemotherapy was given.
The comparison of cardiac events in women irradiated for left-sided versus right-sided breast cancer represents a comparison of higher versus lower radiation dose. Up until 2002 radiotherapy regimens in Denmark were identical in women with left-sided and right-sided breast cancer. During 2003–2005 some women were entered into the DBCG-IMN study in which internal mammary node radiation was given to women with right-sided but not with left-sided breast cancer [16]. This may be one of the reasons for the increased breast cancer and all-cause mortality rates among women with left-sided cancer who received both radiotherapy and anthracyclines (Table S2). Even for the women in this study, however, cardiac doses were higher in women with left-sided than right-sided breast cancer. In most countries, the ratio of dose in left-sided versus right-sided breast cancer varies substantially according to the regions irradiated [17]. We did not have heart dose information for the individual women in our study. Nevertheless, a study of heart doses from Danish breast cancer regimens used during 1977–2001 has shown that the average mean heart dose was around 6 Gy for left-sided RT and around 2–3 Gy for right-sided radiotherapy [18] though with considerable variation from 1 Gy to 8 Gy for left-sided tangential radiotherapy [19].

In this study, the number of women receiving both radiotherapy and anthracyclines was limited and the length of follow-up was relatively short which is clearly a limitation of our study. In addition, women selected for chemotherapy with anthracyclines are less likely to suffer from heart disease at diagnosis. The study also has some further limitations. First, the cardiology records of patients recorded with heart disease were not examined to confirm diagnoses from the Danish NPR. Second, for angina it is possible that women who developed chest pain after receiving left-sided radiotherapy may have been more frequently investigated, and diagnosed with angina than women receiving right-sided radiotherapy. This may have affected our IRR, LVR ratios for angina. Third, we were not able to examine the effect of trastuzumab because no women in our study received it.

Implications

Our results have implications for assessment of the risk of today’s breast cancer radiotherapy. They confirm the excess of ischaemic heart disease from breast cancer radiotherapy seen in previous studies and suggest that the effect of radiotherapy on the heart may be increased by anthracyclines. From a clinical point of view, every possible effort should be made to reduce the dose to the heart in breast cancer radiotherapy but without compromising the coverage of the target, thus maintaining the beneficial effect of radiotherapy.

Conclusion

Radiotherapy for left-sided breast cancer is associated with a higher risk of heart disease than for right-sided with the largest increases seen in women who also received anthracycline-containing chemotherapy.

Funding

Oxford funding was provided by Cancer Research UK (grant C8225/A21133) and by core funding to the Clinical Trial Service Unit (from Cancer Research UK, Medical Research Council, British Heart Foundation), the British Heart Foundation Centre for Research Excellence (Grant No. RE/13/1/30181), and the UK Department of Health Policy Research Programme (Studies of Ionising Radiation and the Risk of Heart Disease, 091/0203).

Conflict of interest statement

None of the authors disclose any financial or personal relationships with other persons or organizations that could inappropriately influence their work.

Acknowledgements

Thanks to the Danish Breast Cancer Cooperative Group, the Danish National Patient Register and the Danish Register of Causes of Death for providing data. Inquiries regarding accessing the data should be addressed to the Danish Breast Cancer Cooperative Group.

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at http://dx.doi.org/10.1016/j.radonc.2017.03.012.

References

[1] Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Darby S, McGale P, Correa C, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 2011;378:1707–16.
[2] Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), McGale P, Taylor C, Correa C, et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet 2014;383:2127–35.
[3] Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;366:2087–106.
[4] McGale P, Darby SC, Hall P, et al. Incidence of heart disease in 35,000 women treated with radiotherapy for breast cancer in Denmark and Sweden. Radiother Oncol 2011;100:167–75.
[5] Ejlertsen B, Mouridsen HT, Jensen MB, et al. Improved outcome from substituting methotrexate with epirubicin: Results from a randomised comparison of CMF versus CEF in patients with primary breast cancer. EJC 2007;43:877–84.
[6] Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Peto R, Davies C, Godwin J, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 2012 Feb 4;379(9814):432–44.
[7] Ryberg M, Nielsen D, Cortese G, Nielsen G, Skovsgaard T, Andersen PK. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients. J Natl Cancer Inst 2008;100:1058–67.
[8] Sawyer DB. Anthracyclines and heart failure. N Engl J Med 2013;368:1154–6.
[9] Christensen P, Ejlertsen B, Jensen M-B, Mouridsen H, Danish Breast Cancer Cooperative Group. Clin Epidemiol 2016;8:445–9.
[10] Helweg-Larsen K. The Danish register of causes of death. Scand J Public Health 2011;39:26–9.
[11] Lyngé E, Sandegaard JL, Rebolj M. The Danish national patient register. Scand J Public Health 2011;39:30–3.
[12] dos Santos Silva I. Evaluating the role of chance. In: Cancer epidemiology: principles and methods. IARC, World Health Organization; 1999. ISBN 978-92-832-0405-3. p. 103–34.
[13] Release 13. College Station TX: StataCorp LP; 2013. Stata Statistical Software.
[14] Cutrer DJ, Taylor CW, Rahimi K, McGale P, Ferreira V, Darby S. Effects of radiation therapy on the cardiovascular system. In: Ewer MS, Yeh ETH, editors. Cancer and the heart 2nd edition. USA: People’s Medical Publishing House; 2013. p. 83–131.
[15] Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 2013;368:987–98.
[16] Thorsen LB, Offersen BV, Danø H, et al. DBCG-IMN: a population-based cohort study on the effect of internal mammary node irradiation in early node-positive breast cancer. J Clin Oncol 2016 Feb 1;34(4):314–20.
[17] Taylor CW, Nisbet A, McGale P, et al. Cardiac exposures in breast cancer radiotherapy: 1950s to 1990s. Int J Radiat Oncol Biol Phys 2007;69:1484–95.
[18] Taylor CW, Brommum D, Darby SC, et al. Cardiac dose estimates from Danish and Swedish breast cancer radiotherapy during 1977–2001. Radiother Oncol 2011;100:176–83.
[19] Lorenzen EL, Brink C, Taylor CW, Darby SC, Ewertz M. Uncertainties in estimating heart doses from 2D-tangential breast cancer radiotherapy. Radiat Oncol 2016 Apr;11(1):71–6.